Science and tech firm Schrodinger Q2 revenue beats expectations
Overview
Schrodinger Q2 2025 rev rises 16% to $54.8 mln, beating analyst expectations
Company maintains full-year 2025 revenue growth guidance, lowers operating expense guidance
Initial clinical data for SGR-3515 and SGR-2921 expected in Q4 2025
Outlook
Schrödinger expects 2025 software revenue growth of 10% to 15%
Company forecasts drug discovery revenue of $45 mln to $50 mln in 2025
Software gross margin for 2025 expected to be 74% to 75%
Operating expenses in 2025 expected to be lower than 2024
Result Drivers
SOFTWARE REVENUE - Increase driven by hosted contracts and contribution revenue, partially offset by prior multi-year on-premise contracts
DRUG DISCOVERY REVENUE - Growth attributed to increased activity in drug discovery segment
LOWER OPERATING EXPENSES - Decrease due to reduced R&D expenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $54.80 mln | $52 mln (8 Analysts) |
Q2 Net Income | -$43.20 mln | ||
Q2 Software Gross Margin | 68.0% | ||
Q2 Gross Profit | $26.16 mln | ||
Q2 Operating Expenses | $79.10 mln | ||
Q2 Software Revenue | $40.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Schrodinger Inc is $31.00, about 36.6% above its August 5 closing price of $19.64
Press Release:
